Market Place
Sourcing Support
Zentalis Pharmaceuticals Announces Key Management Appointments
12 Dec 2024 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
02 Dec 2024 //
GLOBENEWSWIRE
Zentalis Pharma Announces Exec Changes for Azenosertib Studies
13 Nov 2024 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
01 Nov 2024 //
GLOBENEWSWIRE
FDA Lifts Partial Hold On Zentalis` Azenosertib Studies
16 Sep 2024 //
GLOBENEWSWIRE
Zentalis Pharma to Present Preclinical Azenosertib Data at ESMO 2024
09 Sep 2024 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Announces Inducement Grants per Nasdaq Rule 5635(c)(4)
03 Sep 2024 //
GLOBENEWSWIRE
Zentalis Reports Q2 2024 Results And Operational Progress
09 Aug 2024 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Announces Inducement Grants
01 Aug 2024 //
GLOBENEWSWIRE
Zentalis Grants Inducements Under Nasdaq Rule 5635(c)(4)
01 Jul 2024 //
GLOBENEWSWIRE
Zentalis Hit With FDA Partial Clinical Hold on Cancer Studies,Patient Deaths
19 Jun 2024 //
BIOSPACE
Zentalis Announces Nasdaq Employee Inducement Grants
03 Jun 2024 //
GLOBENEWSWIRE
Zentalis At Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Zentalis Appoints Luke Walker To Board For Oncology Expertise
29 May 2024 //
GLOBENEWSWIRE
Zentalis Azenosertib Gemcitabine: Osteosarcoma Phase 1 At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Zentalis To Present At TD Cowen Oncology Innovation Summit
14 May 2024 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Q1 2024 Results And Operational Progress
07 May 2024 //
GLOBENEWSWIRE
Zentalis: Inducement Grants Under Nasdaq Rule 5635(c)(4)
01 May 2024 //
GLOBENEWSWIRE
Zentalis to Highlight Preclinical Data Demonstrating Azenosertib at AACR
02 Apr 2024 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2024 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2024 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
28 Feb 2024 //
GLOBENEWSWIRE
Zentalis Reports Full Year 2023 Financial Results and Operational Updates
27 Feb 2024 //
GLOBENEWSWIRE
Zentalis to Participate in the Oppenheimer Healthcare Life Sciences Conference
13 Feb 2024 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2024 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
25 Jan 2024 //
GLOBENEWSWIRE
Immunome Licenses Zentalis ROR1 Antibody-Drug Conjugate
08 Jan 2024 //
BUSINESSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jan 2024 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Dec 2023 //
GLOBENEWSWIRE
Zentalis to Participate in Investor Call
09 Nov 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Nov 2023 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Oct 2023 //
GLOBENEWSWIRE
Zentalis to Participate in Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Sep 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
01 Aug 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering
15 Jun 2023 //
GLOBENEWSWIRE
Zentalis Announces Azenosertib Dosing Doubles Efficacy Over Continuous Dosing
06 Jun 2023 //
GLOBENEWSWIRE
Zentalis Announces Presentation of Phase 1b Data Demonstrating Azenosertib
25 May 2023 //
GLOBENEWSWIRE
Zentalis to Host Call to Provide Update with Efficacy Results for Azenosertib
23 May 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Reports 1Q 2023FYR &Operational Updates
10 May 2023 //
GLOBENEWSWIRE
Zentalis to present +VE clinical data in ovarian cancer combining azenosertib
26 Apr 2023 //
GLOBENEWSWIRE
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marke
17 Apr 2023 //
GLOBENEWSWIRE
Zentalis Pharma Reports Full Year 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
13 Feb 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
01 Feb 2023 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Feb 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
03 Jan 2023 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
01 Dec 2022 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference
08 Nov 2022 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule
01 Nov 2022 //
GLOBENEWSWIRE
Zentalis Announces First ZN-c3 Clinical Development Collaboration with Pfizer
24 Oct 2022 //
GLOBENEWSWIRE
Zentalis Appoints Mark Lackner as CTOr, Head of Biomarker Strategy
17 Oct 2022 //
GLOBENEWSWIRE
Zentalis Appoints Dr. Mark Lackner as CTO, Head of Biomarker Strategy
17 Oct 2022 //
GLOBENEWSWIRE
Zentalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2022 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to CSO
27 Sep 2022 //
GLOBENEWSWIRE
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq
01 Sep 2022 //
GLOBENEWSWIRE
